Pharsight

Otrexup is owned by Otter Pharms.

Otrexup contains Methotrexate.

Otrexup has a total of 13 drug patents out of which 0 drug patents have expired.

Otrexup was authorised for market use on 11 October, 2013.

Otrexup is available in solution;subcutaneous dosage forms.

Otrexup can be used as subcutaneous injection of methotrexate.

The generics of Otrexup are possible to be released after 27 May, 2031.

Application	Filing Date	Opposition Party	Legal Status
EP19150366A	2022-09-04	Bandpay & Greuter	Granted and Under Opposition
EP06719329A	2019-10-07	Bandpay & Greuter	Granted and Under Opposition
EP09719763A	2016-06-16	Ypsomed AG	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446441	OTTER PHARMS	Prefilled syringe injector	Jan, 2026 (2 years from now)
US9629959	OTTER PHARMS	Prefilled syringe jet injector	Jan, 2026 (2 years from now)
US9533102	OTTER PHARMS	Prefilled syringe jet injector	Jan, 2026 (2 years from now)
US8562564	OTTER PHARMS	Prefilled syringe jet injector	Jan, 2026 (2 years from now)
US8021335	OTTER PHARMS	Prefilled syringe jet injector	Oct, 2026 (3 years from now)
US9867949	OTTER PHARMS	Injector safety device	Mar, 2029 (5 years from now)
US10709844	OTTER PHARMS	Injector safety device	Mar, 2029 (5 years from now)
US11497753	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US8579865	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US8945063	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US9421333	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US8480631	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US8814834	OTTER PHARMS	Injector safety device	May, 2031 (8 years from now)

Market Authorisation Date: 11 October, 2013

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS